{"url":"https://lda.senate.gov/api/v1/filings/49a7d4eb-03f8-4e1a-b1ea-3b7c6acf2cae/","filing_uuid":"49a7d4eb-03f8-4e1a-b1ea-3b7c6acf2cae","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2021,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/49a7d4eb-03f8-4e1a-b1ea-3b7c6acf2cae/print/","filing_document_content_type":"text/html","income":null,"expenses":"170000.00","expenses_method":"a","expenses_method_display":"Method A - Reporting amounts using LDA definitions only","posted_by_name":"Jennie Skelton","dt_posted":"2021-10-20T11:36:47.713000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"60 Binney Street","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Cambridge","registrant_state":"MA","registrant_zip":"02142","registrant":{"id":401105284,"url":"https://lda.senate.gov/api/v1/registrants/401105284/","house_registrant_id":null,"name":"BLUEBIRD BIO, INC.","description":"Pharmaceuticals","address_1":"455 Grand Union Boulevard","address_2":null,"address_3":null,"address_4":null,"city":"Somerville","state":"MA","state_display":"Massachusetts","zip":"02145","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JENNIE SKELTON","contact_telephone":"+1 415-903-2800","dt_updated":"2025-05-06T14:43:10.588302-04:00"},"client":{"id":203495,"url":"https://lda.senate.gov/api/v1/clients/203495/","client_id":12,"name":"BLUEBIRD BIO, INC.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2021-07-16"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Gene therapy, rare diseases, FDA/CMC flexibility, value-based pricing legislation, Cures 2.0, 85 FR 87000","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":121570,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":"CUDWORTH","last_name":"ARBES","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}